Hims & Hers Health, Inc. (HIMS)
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circling the wreckage.
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell?
Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Health: The Stock Is On Sale, Buy It
Hims & Hers Health delivered a misunderstood Q1-26, raising FY-26 guidance and reaffirming 2030 revenue and EBITDA targets despite negative sentiment. The transition from compounded to branded GLP-1s pressured margins, but normalized gross margins remain robust and marketing spend is a lever for profitability. Subscriber growth is poised to reaccelerate, with expectations of 100k new weight loss subscribers per month via the Novo partnership, supporting a 30–35% YoY increase.
Hims & Hers Health: The Market Is Selling The Wrong Quarter
I'm upgrading Hims & Hers Health to a buy as the branded GLP-1 transition outpaces my expectations, in turn restores growth visibility. HIMS shipped 125,000 Wegovy units in six weeks, and management is now guiding for 100,000+ monthly weight-loss subscriber additions. My three main concerns, including identity crisis, growth engine, and regulatory overhang, are resolved, but margin compression remains a risk.
Hims & Hers Health: The Real Story Begins
Hims & Hers Health raised FY2026 revenue guidance to $2.8-$3.0 billion despite reporting a heavily distorted quarterly EPS loss. More than 125,000 Wegovy shipments in six weeks suggest Novo conversion rates are materially outperforming bearish expectations. Gross margin fell to 65%, but adjusted gross margin exceeded 70% after excluding $33 million in restructuring charges.
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin Down
HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.
Hims & Hers shares plummet on first quarter earnings miss
Hims & Hers (NYSE:HIMS) reported first quarter financial results that included a wider-than-expected loss and softer revenue performance, sending shares down nearly 14% to about $25 on Tuesday morning. For the quarter, the telehealth company posted a net loss of $92.1 million, or $0.40 loss per share, compared with a net profit of $49.5 million in the same period last year.
Hims & Hers: I See No New Red Flags
Hims & Hers stock is crashing in pre-market trading, down about 14%, after reporting a disastrous Q1 and an upbeat Q2 outlook. We don't find Q1 weakness surprising due to the Novo deal timing and tough Y/Y comparison with 1Q25. We understand that investors wanted more from print after the stock doubled from $14 lows, but we remain confident that, post-expectation reset, HIMS will be better positioned to beat expectations.
U.S.-Iran Ceasefire on "Life Support," HIMS & ASTS Earnings Sell-Off
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines come head-to-head with the red-hot tech rally.
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
